Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study

Next Previous
X
Search
Trial Profile

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Levofolinic acid
  • Indications Colorectal cancer; Gastric cancer; Neuroendocrine carcinoma; Oesophageal cancer; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms BEVANEC; PRODIGE 41-BEVANEC

    • Most Recent Events

    • 02 Dec 2024 Status changed from active, no longer recruiting to completed.
    • 15 Sep 2024 This study has been completed in France as per European Clinical Trials Database.
    • 02 Feb 2023 Results (Between Sept 5, 2017, and Feb 8, 2022) assessing the efficacy of FOLFIRI plus bevacizumab, and FOLFIRI alone, in patients with advanced neuroendocrine carcinoma, published in the Lancet Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top